| Literature DB >> 22390946 |
Gohar Fakhfouri1, Reza Rahimian, Jean-Eric Ghia, Waliul I Khan, Ahmad R Dehpour.
Abstract
In this article we discuss the novel pharmacological aspects of 5-HT(3) receptor antagonists. Commonly used to counteract chemotherapy-induced emesis, these agents now appear to be reaching out for newer indications. Studies have reported neuroprotective and anti-inflammatory properties in vitro and in vivo. 5-HT(3) receptor antagonists can modulate the immune-inflammatory axis through blockade of 5-HT(3) receptors present on immune cells. We review evidence addressing the effects of these drugs on peripheral inflammatory diseases, including asthma, rheumatoid diseases, inflammatory bowel disease and sepsis in addition to diabetes and CNS disorders, including Alzheimer's disease (AD), seizure and stroke.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22390946 DOI: 10.1016/j.drudis.2012.02.009
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851